Activation of Macrophages and Microglia by Interferon– γ and Lipopolysaccharide Increases Methylglyoxal Production: A New Mechanism in the Development of Vascular Complications and Cognitive Decline in Type 2 Diabetes Mellitus?
Restricted accessResearch articleFirst published online July 17, 2017
Activation of Macrophages and Microglia by Interferon– γ and Lipopolysaccharide Increases Methylglyoxal Production: A New Mechanism in the Development of Vascular Complications and Cognitive Decline in Type 2 Diabetes Mellitus?
Methylglyoxal (MGO), a dicarbonyl compound derived from glucose, is elevated in diabetes mellitus and contributes to vascular complications by crosslinking collagen and increasing arterial stiffness. It is known that MGO contributes to inflammation as it forms advanced glycation end products (AGEs), which activate macrophages via the receptor RAGE. The aim of study was to investigate whether inflammatory activation can increase MGO levels, thereby completing a vicious cycle. In order to validate this, macrophage (RAW264.7, J774A.1) and microglial (N11) cells were stimulated with IFN-γ and LPS (5 + 5 and 10 + 10 IFN-γ U/ml or μg/ml LPS), and extracellular MGO concentration was determined after derivatization with 5,6-Diamino-2,4-dihydroxypyrimidine sulfate by HPLC. MGO levels in activated macrophage cells (RAW264.7) peaked at 48 h, increasing 2.86-fold (3.14±0.4 μM) at 5 U/ml IFN-γ+5 μg/ml LPS, and 4.74-fold (5.46±0.30 μM) at 10 U/ml IFN-γ+10 μg/ml LPS compared to the non-activated controls (1.15±0.02 μM). The other two cell lines, J774A.1 macrophages and N11 microglia, showed a similar response. We suggest that inflammation increases MGO production, possibly exacerbating arterial stiffness, cardiovascular complications, and diabetes-related cognitive decline.
ChatterjeeS, PetersSA, WoodwardM, Mejia ArangoS, BattyGD, BeckettN, BeiserA, BorensteinAR, CranePK, HaanM, HassingLB, HaydenKM, KiyoharaY, LarsonEB, LiCY, NinomiyaT, OharaT, PetersR, RussTC, SeshadriS, StrandBH, WalkerR, XuW, HuxleyRR (2016) Type 2 diabetes as a risk factor for dementia in women compared with men: A pooled analysis of 2.3 million people comprising more than 100,000 cases of dementia. Diabetes Care39, 300–307.
2.
Ravona-SpringerR, Schnaider-BeeriM (2011) The association of diabetes and dementia and possible implications for nondiabetic populations. Expert Rev Neurother11, 1609–1617.
3.
PeilaR, RodriguezBL, LaunerLJ; Honolulu-Asia Aging Study (2002) Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: The Honolulu-Asia Aging Study. Diabetes51, 1256–1262.
4.
OttA, StolkRP, van HarskampF, PolsHA, HofmanA, BretelerMM (1999) Diabetes mellitus and the risk of dementia: The Rotterdam Study. Neurology53, 1937–1942.
5.
JansonJ, LaedtkeT, ParisiJE, O’BrienP, PetersenRC, ButlerPC (2004) Increased risk of type 2 diabetes in Alzheimer disease. Diabetes53, 474–481.
6.
ArvanitakisZ, WilsonRS, BieniasJL, EvansDA, BennettDA (2004) Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function. Arch Neurol61, 661–666.
7.
MoranC, BeareR, PhanTG, BruceDG, CallisayaML, SrikanthV; Alzheimer’s Disease Neuroimaging Initiative (ADNI) (2015) Type 2 diabetes mellitus and biomarkers of neurodegeneration. Neurology85, 1123–1130.
8.
MoranC, MünchG, ForbesJM, BeareR, BlizzardL, VennAJ, PhanTG, ChenJ, SrikanthV (2015) Type 2 diabetes, skin autofluorescence, and brain atrophy. Diabetes64, 279–283.
9.
UmegakiH (2014) Type 2 diabetes as a risk factor for cognitive impairment: Current insights. Clin Interv Aging9, 1011–1019.
10.
WilcoxG (2005) Insulin and insulin resistance. Clin Biochem Rev26, 19–39.
11.
GiuglianoD, CerielloA, EspositoK (2008) Glucose metabolism and hyperglycemia. Am J Clin Nutr87, 217S–222S.
12.
FerranniniE, LanfranchiA, Rohner-JeanrenaudF, ManfrediniG, Van de WerveG (1990) Influence of long-term diabetes on liver glycogen metabolism in the rat. Metabolism39, 1082–1088.
13.
MünchG, ThomeJ, FoleyP, SchinzelR, RiedererP (1997) Advanced glycation endproducts in ageing and Alzheimer’s disease. Brain Res Brain Res Rev23, 134–143.
14.
MünchG, SchicktanzD, BehmeA, GerlachM, RiedererP, PalmD, SchinzelR (1999) Amino acid specificity of glycation and protein-AGE crosslinking reactivities determined with a dipeptide SPOT library. Nat Biotechnol17, 1006–1010.
15.
SinghVP, BaliA, SinghN, JaggiAS (2014) Advanced glycation end products and diabetic complications. Korean J Physiol Pharmacol18, 1–14.
16.
MonnierVM, NagarajRH, Portero-OtinM, GlombM, ElgawishAH, SellDR, FriedlanderMA (1996) Structure of advanced Maillard reaction products and their pathological role. Nephrol Dial Transplant11(Suppl 5), 20–26.
17.
AllamanI, BélangerM, MagistrettiPJ (2015) Methylglyoxal, the dark side of glycolysis. Front Neurosci9, 23.
18.
AyalaA, MuñozMF, ArgüellesS (2014) Lipid peroxidation: Production, metabolism, and signaling mechanisms of malondialdehyde and 4-hydroxy-2-nonenal. Oxid Med Cell Longev2014, 360438.
19.
Negre-SalvayreA, CoatrieuxC, IngueneauC, SalvayreR (2008) Advanced lipid peroxidation end products in oxidative damage to proteins. Potential role in diseases and therapeutic prospects for the inhibitors. Br J Pharmacol153, 6–20.
20.
OdaniH, ShinzatoT, UsamiJ, MatsumotoY, Brinkmann FryeE, BaynesJW, MaedaK (1998) Imidazolium crosslinks derived from reaction of lysine with glyoxal and methylglyoxal are increased in serum proteins of uremic patients: Evidence for increased oxidative stress in uremia. FEBS Letters427, 381–385.
21.
ShamsiFA, PartalA, SadyC, GlombMA, NagarajRH (1998) Immunological evidence for methylglyoxal-derived modifications in vivo. Determination of antigenic epitopes. J Biol Chem273, 6928–6936.
22.
TakeuchiM, TakinoJ, FurunoS, ShiraiH, KawakamiM, MuramatsuM, KobayashiY, YamagishiS (2015) Assessment of the concentrations of various advanced glycation end-products in beverages and foods that are commonly consumed in Japan. PLoS One10, e0118652.
23.
HeC, SabolJ, MitsuhashiT, VlassaraH (1999) Dietary glycotoxins: Inhibition of reactive products by aminoguanidine facilitates renal clearance and reduces tissue sequestration. Diabetes48, 1308–1315.
24.
NowotnyK, JungT, HöhnA, WeberD, GruneT (2015) Advanced glycation end products and oxidative stress in type 2 diabetes mellitus. Biomolecules5, 194–222.
25.
BidaseeKR, ZhangY, ShaoCH, WangM, PatelKP, DincerUD, BeschHRJr (2004) Diabetes increases formation of advanced glycation end products on Sarco(endo)plasmic reticulum Ca2+-ATPase. Diabetes53, 463–473.
26.
MilneR, BrownsteinS (2013) Advanced glycation end products and diabetic retinopathy. Amino Acids44, 1397–1407.
27.
SharmaY, SaxenaS, MishraA, SaxenaA, NatuSM (2013) Advanced glycation end products and diabetic retinopathy. J Ocul Biol Dis Infor5, 63–69.
28.
ChenM, CurtisTM, StittAW (2013) Advanced glycation end products and diabetic retinopathy. Curr Med Chem20, 3234–3240.
29.
ThomasMC, ForbesJM, CooperME (2005) Advanced glycation end products and diabetic nephropathy. Am J Ther12, 562–572.
WangP, HuangR, LuS, XiaW, CaiR, SunH, WangS (2016) RAGE and AGEs in mild cognitive impairment of diabetic patients: A cross-sectional study. PLoS One11, e0145521.
32.
SpauwenPJ, van EupenMG, KöhlerS, StehouwerCD, VerheyFR, van der KallenCJ, SepSJ, KosterA, SchaperNC, DagneliePC, SchalkwijkCG, SchramMT, van BoxtelMP (2015) Associations of advanced glycation end-products with cognitive functions in individuals with and without type 2 diabetes: The Maastricht Study. J Clin Endocrinol Metab100, 951–960.
33.
LovestoneS, SmithU (2014) Advanced glycation end products, dementia, and diabetes. Proc Natl Acad Sci U S A111, 4743–4744.
34.
LiuCY, HuangQF, ChengYB, GuoQH, ChenQ, LiY, WangJG (2017) A comparative study on skin and plasma advanced glycation end products and their associations with arterial stiffness. Pulse (Basel)4, 208–218.
35.
GoldinA, BeckmanJA, SchmidtAM, CreagerMA (2006) Advanced glycation end products: Sparking the development of diabetic vascular injury. Circulation114, 597–605.
36.
ZiemanSJ, MelenovskyV, KassDA (2005) Mechanisms, pathophysiology, and therapy of arterial stiffness. Arterioscler Thromb Vasc Biol25, 932–943.
37.
LaurentS, BoutouyrieP, LacolleyP (2005) Structural and genetic bases of arterial stiffness. Hypertension45, 1050–1055.
KangKT (2014) Endothelium-derived relaxing factors of small resistance arteries in hypertension. Toxicol Res30, 141–148.
44.
BusseR, FlemingI (1998) Pulsatile stretch and shear stress: Physical stimuli determining the production of endothelium-derived relaxing factors. J Vasc Res35, 73–84.
45.
KimuraH, EsumiH (2003) Reciprocal regulation between nitric oxide and vascular endothelial growth factor in angiogenesis. Acta Biochim Pol50, 49–59.
46.
PapapetropoulosA, García-CardeñaG, MadriJA, SessaWC (1997) Nitric oxide production contributes to the angiogenic properties of vascular endothelial growth factor in human endothelial cells. J Clin Invest100, 3131–3139.
47.
DulakJ, JózkowiczA, Dembinska-KiecA, GuevaraI, ZdzienickaA, Zmudzinska-GrochotD, FlorekI, WójtowiczA, SzubaA, CookeJP (2000) Nitric oxide induces the synthesis of vascular endothelial growth factor by rat vascular smooth muscle cells. Arterioscler Thromb Vasc Biol20, 659–666.
48.
YangJ, ZhangL, YuC, YangXF, WangH (2014) Monocyte and macrophage differentiation: Circulation inflammatory monocyte as biomarker for inflammatory diseases. Biomark Res2, 1.
49.
LeyK, MillerYI, HedrickCC (2011) Monocyte and macrophage dynamics during atherogenesis. Arterioscler Thromb Vasc Biol31, 1506–1516.
50.
JaipersadAS, LipGY, SilvermanS, ShantsilaE (2014) The role of monocytes in angiogenesis and atherosclerosis. J Am Coll Cardiol63, 1–11.
51.
MooreKJ, SheedyFJ, FisherEA (2013) Macrophages in atherosclerosis: A dynamic balance. Nat Rev Immunol13, 709–721.
52.
ChenJ, YongY, XingM, GuY, ZhangZ, ZhangS, LuL (2013) Characterization of polysaccharides with marked inhibitory effect on lipid accumulation in Pleurotus eryngii. Carbohydr Polym97, 604–613.
53.
RaderDJ, PuréE (2005) Lipoproteins, macrophage function, and atherosclerosis: Beyond the foam cell?Cell Metab1, 223–230.
54.
RolfeBE, CampbellJH, SmithNJ, CheongMW, CampbellGR (1995) T lymphocytes affect smooth muscle cell phenotype and proliferation. Arterioscler Thromb Vasc Biol15, 1204–1210.
BahramsoltaniM, SlosarekI, De SpiegelaereW, PlendlJ (2014) Angiogenesis and collagen type IV expression in different endothelial cell culture systems. Anat Histol Embryol43, 103–115.
57.
ZordanP, RigamontiE, FreudenbergK, ContiV, AzzoniE, Rovere-QueriniP, BrunelliS (2014) Macrophages commit postnatal endothelium-derived progenitors to angiogenesis and restrict endothelial to mesenchymal transition during muscle regeneration. Cell Death Dis5, e1031.
58.
van der WalAC, BeckerAE (1999) Atherosclerotic plaque rupture – pathologic basis of plaque stability and instability. Cardiovasc Res41, 334–344.
59.
SinghRB, MengiSA, XuYJ, ArnejaAS, DhallaNS (2002) Pathogenesis of atherosclerosis: A multifactorial process. Exp Clin Cardiol7, 40–53.
60.
LibbyP (2013) Collagenases and cracks in the plaque. J Clin Invest123, 3201–3203.
61.
SrikanthV, MaczurekA, PhanT, SteeleM, WestcottB, JuskiwD, MünchG (2011) Advanced glycation endproducts and their receptor RAGE in Alzheimer’s disease. Neurobiol Aging32, 763–777.
62.
RamasamyR, YanSF, SchmidtAM (2011) Receptor for AGE (RAGE): Signaling mechanisms in the pathogenesis of diabetes and its complications. Ann N Y Acad Sci1243, 88–102.
63.
MuscatS, PelkaJ, HegeleJ, WeigleB, MünchG, PischetsriederM (2007) Coffee and Maillard products activate NF-kappaB in macrophages via H2O2 production. Mol Nutr Food Res51, 525–535.
64.
BerbaumK, ShanmugamK, StuchburyG, WiedeF, KörnerH, MünchG (2008) Induction of novel cytokines and chemokines by advanced glycation endproducts determined with a cytometric bead array. Cytokine41, 198–203.
65.
MaczurekA, ShanmugamK, MünchG (2008) Inflammation and the redox-sensitive AGE-RAGE pathway as a therapeutic target in Alzheimer’s disease. Ann N Y Acad Sci1126, 147–151.
66.
VlassaraH, FuhH, DonnellyT, CybulskyM (1995) Advanced glycation endproducts promote adhesion molecule (VCAM-1, ICAM-1) expression and atheroma formation in normal rabbits. Mol Med1, 447–456.
67.
KuntT, ForstT, HarzerO, BuchertG, PfütznerA, LöbigM, ZschäbitzA, StofftE, EngelbachM, BeyerJ (1998) The influence of advanced glycation endproducts (AGE) on the expression of human endothelial adhesion molecules. Exp Clin Endocrinol Diabetes106, 183–188.
68.
BadimonL, PadróT, VilahurG (2012) Atherosclerosis, platelets and thrombosis in acute ischaemic heart disease. Eur Heart J Acute Cardiovasc Care1, 60–74.
69.
OrekhovAN, BobryshevYV, ChistiakovDA (2014) The complexity of cell composition of the intima of large arteries: Focus on pericyte-like cells. Cardiovasc Res103, 438–451.
70.
FrostegårdJ (2013) Immunity, atherosclerosis and cardiovascular disease. BMC Med11, 117.
71.
HeydenS, GerberCJ (1969) Atherosclerotic cerebrovascular disease-its nature and management. Am J Med46, 763–773.
72.
IadecolaC (2013) The pathobiology of vascular dementia. Neuron80, 844–866.
73.
de la TorreJC (2012) Cardiovascular risk factors promote brain hypoperfusion leading to cognitive decline and dementia. Cardiovasc Psychiatry Neurol2012, 367516.
74.
ShuaibA, ButcherK, MohammadAA, SaqqurM, LiebeskindDS (2011) Collateral blood vessels in acute ischaemic stroke: A potential therapeutic target. Lancet Neurol10, 909–921.
StrongAJ, SmithSE, WhittingtonDJ, MeldrumBS, ParsonsAA, KrupinskiJ, HunterAJ, PatelS, RobertsonC (2000) Factors influencing the frequency of fluorescence transients as markers of peri-infarct depolarizations in focal cerebral ischemia. Stroke31, 214–222.
BiesselsGJ, ReijmerYD (2014) Brain changes underlying cognitive dysfunction in diabetes: What can we learn from MRI?Diabetes63, 2244–2252.
84.
KawamuraT, UmemuraT, HottaN (2012) Cognitive impairment in diabetic patients: Can diabetic control prevent cognitive decline?J Diabetes Investig3, 413–423.
85.
HussainS, MansouriS, SjöholmA, PatroneC, DarsaliaV (2014) Evidence for cortical neuronal loss in male type 2 diabetic Goto-Kakizaki rats. J Alzheimers Dis41, 551–560.
86.
SrikanthV, WestcottB, ForbesJ, PhanTG, BeareR, VennA, PearsonS, GreenawayT, ParameswaranV, MünchG (2013) Methylglyoxal, cognitive function and cerebral atrophy in older people. J Gerontol A Biol Sci Med Sci68, 68–73.
87.
Gorska-CiebiadaM, Saryusz-WolskaM, BorkowskaA, CiebiadaM, LobaJ (2015) C-reactive protein, advanced glycation end products, and their receptor in type 2 diabetic, elderly patients with mild cognitive impairment. Front Aging Neurosci7, 209.
88.
BeeriMS, MoshierE, SchmeidlerJ, GodboldJ, UribarriJ, ReddyS, SanoM, GrossmanHT, CaiW, VlassaraH, SilvermanJM (2011) Serum concentration of an inflammatory glycotoxin, methylglyoxal, is associated with increased cognitive decline in elderly individuals. Mech Ageing Dev132, 583–587.
GunawardenaD, BennettL, ShanmugamK, KingK, WilliamsR, ZabarasD, HeadR, OoiL, GyengesiE, MünchG (2014) Anti-inflammatory effects of five commercially available mushroom species determined in lipopolysaccharide and interferon-γ activated murine macrophages. Food Chem148, 92–96.
91.
GunawardenaD, KarunaweeraN, LeeS, van Der KooyF, HarmanDG, RajuR, BennettL, GyengesiE, SucherNJ, MünchG (2015) Anti-inflammatory activity of cinnamon (C. zeylanicum and C. cassia) extracts - identification of E-cinnamaldehyde and o-methoxy cinnamaldehyde as the most potent bioactive compounds. Food Funct6, 910–919.
92.
GunawardenaD, ShanmugamK, LowM, BennettL, GovindaraghavanS, HeadR, OoiL, MünchG (2014) Determination of anti-inflammatory activities of standardised preparations of plant- and mushroom-based foods. Eur J Nutr53, 335–343.
93.
Espinosa-MansillaA, Durán-MerásI, CañadaFC, MárquezMP (2007) High-performance liquid chromatographic determination of glyoxal and methylglyoxal in urine by prederivatization to lumazinic rings using in serial fast scan fluorimetric and diode array detectors. Anal Biochem371, 82–91.
94.
Anoopkumar-DukieS, CareyJB, ConereT, O’SullivanE, van PeltFN, AllshireA (2005) Resazurin assay of radiation response in cultured cells. Br J Radiol78, 945–947.
95.
WongA, Dukic-StefanovicS, Gasic-MilenkovicJ, SchinzelR, WiesingerH, RiedererP, MünchG (2001) Anti-inflammatory antioxidants attenuate the expression of inducible nitric oxide synthase mediated by advanced glycation endproducts in murine microglia. Eur J Neurosci14, 1961–1967.
96.
ThornalleyPJ (1988) Modification of the glyoxalase system in human red blood cells by glucose in vitro. Biochem J254, 751–755.
97.
ChaplenFW, FahlWE, CameronDC (1998) Evidence of high levels of methylglyoxal in cultured Chinese hamster ovary cells. Proc Natl Acad Sci U S A95, 5533–5538.
98.
ParkBS, LeeJO (2013) Recognition of lipopolysaccharide pattern by TLR4 complexes. Exp Mol Med45, e66.
TauG, RothmanP (1999) Biologic functions of the IFN-gamma receptors. Allergy54, 1233–1251.
101.
PlataniasLC (2005) Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat Rev Immunol5, 375–386.
102.
LiQ, CherayilBJ (2003) Role of Toll-like receptor 4 in macrophage activation and tolerance during Salmonella enterica serovar Typhimurium infection. Infect Immun71, 4873–4882.
103.
XuXH, ShahPK, FaureE, EquilsO, ThomasL, FishbeinMC, LuthringerD, XuXP, RajavashisthTB, YanoJ, KaulS, ArditiM (2001) Toll-like receptor-4 is expressed by macrophages in murine and human lipid-rich atherosclerotic plaques and upregulated by oxidized LDL. Circulation104, 3103–3108.
104.
VaureC, LiuY (2014) A comparative review of Toll-like receptor 4 expression and functionality in different animal species. Front Immunol5, 316.
105.
SchumannRR (1992) Function of lipopolysaccharide (LPS)-binding protein (LBP) and CD14, the receptor for LPS/LBP complexes: A short review. Res Immunol143, 11–15.
106.
WrightSD, RamosRA, TobiasPS, UlevitchR, MathisonJ (1990) CD14, a receptor for complexes oflipopolysaccharide (LPS) and LPS binding protein. Science249, 1431–1433.
107.
CalvanoJE, AgneseDM, UmJY, GoshimaM, SinghalR, CoyleSM, ReddellMT, KumarA, CalvanoSE, LowrySF (2003) Modulation of the lipopolysaccharide receptor complex (CD14, TLR4, MD-2) and Toll-like receptor 2 in systemic inflammatory response syndrome-positive patients with and without infection: Relationship to tolerance. Shock20, 415–419.
108.
SchmitzF, MagesJ, HeitA, LangR, WagnerH (2004) Transcriptional activation induced in macrophages by Toll-like receptor (TLR) ligands: From expression profiling to a model of TLR signaling. Eur J Immunol34, 2863–2873.
109.
AnwarMA, BasithS, ChoiS (2013) Negative regulatory approaches to the attenuation of Toll-like receptor signaling. Exp Mol Med45, e11.
110.
NapetschnigJ, WuH (2013) Molecular basis of NF-κB signaling. Annu Rev Biophys42, 443–468.
111.
ChenZJ (2005) Ubiquitin signaling in the NF-kappaB pathway. Nat Cell Biol7, 758–765.
112.
KishimotoK, MatsumotoK, Ninomiya-TsujiJ (2000) TAK1 mitogen-activated protein kinase kinase kinase is activated by autophosphorylation within its activation loop. J Biol Chem275, 7359–7364.
113.
TakaesuG, KishidaS, HiyamaA, YamaguchiK, ShibuyaH, IrieK, Ninomiya-TsujiJ, MatsumotoK (2000) TAB2, a novel adaptor protein, mediates activation of TAK1 MAPKKK by linking TAK1 to TRAF6 in the IL-1 signal transduction pathway. Mol Cell5, 649–658.
114.
SakuraiH, NishiA, SatoN, MizukamiJ, MiyoshiH, SugitaT (2002) TAK1–TAB1 fusion protein: A novel constitutively active mitogen-activatedrotein kinase kinase kinase that stimulates AP-1 and NF-κB signaling pathways. Biochem Biophys Res Commun297, 1277–1281.
115.
Casals-CasasC, ÁlvarezE, SerraM, de la TorreC, FarreraC, Sánchez-TillóE, CaellesC, LloberasJ, CeladaA (2009) CREB and AP-1 activation regulates MKP-1 induction by LPS or M-CSF and their kinetics correlate with macrophage activation versus proliferation. Eur J Immunol39, 1902–1913.
116.
SchroderK, HertzogPJ, RavasiT, HumeDA (2004) Interferon-gamma: An overview of signals, mechanisms and functions. J Leukoc Biol75, 163–189.
117.
DeckerT, KovarikP, MeinkeA (1997) GAS Elements: A few nucleotides with a major impact on cytokine-induced gene expression. J Interferon Cytokine Res17, 121–134.
118.
GaoJ, MorrisonDC, ParmelyTJ, RussellSW, MurphyWJ (1997) An interferon-gamma-activated site (GAS) is necessary for full expression of the mouse iNOS gene in response to interferon-gamma and lipopolysaccharide. J Biol Chem272, 1226–1230.
119.
LucasDM, LokutaMA, McDowellMA, DoanJE, PaulnockDM (1998) Analysis of the IFN-gamma-signaling pathway in macrophages at different stages of maturation. J Immunol160, 4337–4342.
120.
KumatoriA, YangD, SuzukiS, NakamuraM (2002) Cooperation of STAT-1 and IRF-1 in Interferon-γ-induced transcription of the gp91(phox) gene. J Biol Chem277, 9103–9111.
121.
DalpkeAH, EckerleS, FreyM, HeegK (2003) Triggering of Toll-like receptors modulates IFN-gamma signaling: Involvement of serine 727 STAT1 phosphorylation and suppressors of cytokine signaling. Eur J Immunol33, 1776–1787.
122.
SchroderK, SweetMJ, HumeDA (2006) Signal integration between IFNgamma and TLR signalling pathways in macrophages. Immunobiology211, 511–524.
123.
OroszF, OláhJ, OvádiJ (2009) Triosephosphate isomerase deficiency: New insights into an enigmatic disease. Biochim Biophys Acta1792, 1168–1174.
124.
BarerAP (1931) A study of glycolysis. J Clin Invest10, 507–520.
125.
WoodWA (1966) Carbohydrate metabolism. Annu Rev Biochem35, 521–558.
126.
SchomburgD, SalzmannM (1990) Fructose-bisphosphate aldolase In Enzyme Handbook 1: Class 4: Lyases, SchomburgD, SalzmannM, eds.Springer Berlin Heidelberg, Berlin, Heidelberg, pp. 313–320.
HarrisJI WM (1976) Glyceraldehyde 3-phosphate Dehydrogenase. In The Enzymes, PD IB, ed. Academic Press, Inc., New York, pp. 1–49.
129.
DimmelerS, LottspeichF, BrüneB (1992) Nitric oxide causes ADP-ribosylation and inhibition of glyceraldehyde-3-phosphate dehydrogenase. J Biol Chem267, 16771–16774.
130.
HessC, StratmannB, QuesterW, TschoepeD, MadeaB, MusshoffF (2013) Clinical and forensic examinations of glycaemic marker methylglyoxal by means of high performance liquid chromatography-tandem mass spectrometry. Int J Legal Med127, 385–393.
131.
DeponteM (2013) Glutathione catalysis and the reaction mechanisms of glutathione-dependent enzymes. Biochim Biophys Acta1830, 3217–3266.
132.
BraunL, GarzóT, RibaP, MandlJ, KalaposMP (1994) Methylglyoxal and cell viability. Int J Biochem26, 987–990.
133.
ThornalleyPJ (1998) Glutathione-dependent detoxification of alpha-oxoaldehydes by the glyoxalase system: Involvement in disease mechanisms and antiproliferative activity of glyoxalase I inhibitors. Chem Biol Interact111-112, 137–151.
134.
MeisterA (1988) Glutathione metabolism and its selective modification. J Biol Chem263, 17205–17208.
RamanaKV (2011) Aldose reductase: New insights for an old enzyme. Biomol Concepts2, 103–114.
137.
MathebulaSD (2015) Polyol pathway: A possible mechanism of diabetes complications in the eye. Afr Vision Eye Health74, 1–5.
138.
De MattiaG, LaurentiO, BraviC, GhiselliA, IulianoL, BalsanoF (1994) Effect of aldose reductase inhibition on glutathione redox status in erythrocytes of diabetic patients. Metabolism43, 965–968.
139.
AbordoEA, MinhasHS, ThornalleyPJ (1999) Accumulation of alpha-oxoaldehydes during oxidative stress: A role in cytotoxicity. Biochem Pharmacol58, 641–648.
140.
GkogkolouP, BöhmM (2012) Advanced glycation end products: Key players in skin aging?Dermatoendocrinol4, 259–270.
141.
CokerLH, WagenknechtLE (2011) Advanced glycation end products, diabetes, and the brain. Neurology77, 1326–1327.
142.
TangvarasittichaiS (2015) Oxidative stress, insulin resistance, dyslipidemia and type 2 diabetes mellitus. World J Diabetes6, 456–480.
143.
SaviniI, CataniMV, EvangelistaD, GasperiV, AviglianoL (2013) Obesity-associated oxidative stress: Strategies finalized to improve redox state. Int J Mol Sci14, 10497–10538.
144.
ParkK, GrossM, LeeDH, HolvoetP, HimesJH, ShikanyJM, JacobsDRJr (2009) Oxidative stress and insulin resistance: The Coronary Artery Risk Development in Young Adults study. Diabetes Care32, 1302–1307.
145.
YounessiP, YoonessiA (2011) Advanced glycation end-products and their receptor-mediated roles: Inflammation and oxidative stress. Iran J Med Sci36, 154–166.
146.
OttC, JacobsK, HauckeE, Navarrete SantosA, GruneT, SimmA (2014) Role of advanced glycation end products in cellular signaling. Redox Biol2, 411–429.
147.
MorganMJ, LiuZG (2011) Crosstalk of reactive oxygen species and NF-κB signaling. Cell Res21, 103–115.
MercurioF, ManningAM (1999) NF-kappaB as a primary regulator of the stress response. Oncogene18, 6163–6171.
150.
CantyTGJr, BoyleEMJr, FarrA, MorganEN, VerrierED, PohlmanTH (1999) Oxidative stress induces NF-kappaB nuclear translocation without degradation of Ikappa Balpha. Circulation100, II361–II364.
151.
ElmarakbyAA, SullivanJC (2012) Relationship between oxidative stress and inflammatory cytokines in diabetic nephropathy. Cardiovasc Ther30, 49–59.
152.
StentzFB, UmpierrezGE, CuervoR, KitabchiAE (2004) Proinflammatory cytokines, markers of cardiovascular risks, oxidative stress, and lipid peroxidation in patients with hyperglycemic crises. Diabetes53, 2079–2086.
153.
RobertsonRP, HarmonJS (2007) Pancreatic islet beta-cell and oxidative stress: The importance of glutathione peroxidase. FEBS Lett581, 3743–3748.
154.
WuG, FangYZ, YangS, LuptonJR, TurnerND (2004) Glutathione metabolism and its implications for health. J Nutr134, 489–492.
155.
EvansJL, GoldfineID, MadduxBA, GrodskyGM (2002) Oxidative stress and stress-activated signaling pathways: A unifying hypothesis of type 2 diabetes. Endocr Rev23, 599–622.
156.
KongGY, PengZC, CostanzoC, KristenssonK, BentivoglioM (2000) Inducible nitric oxide synthase expression elicited in the mouse brain by inflammatory mediators circulating in the cerebrospinal fluid. Brain Res878, 105–118.
157.
DenlingerLC, FisettePL, GarisKA, KwonG, Vazquez-TorresA, SimonAD, NguyenB, ProctorRA, BerticsPJ, CorbettJA (1996) Regulation of inducible nitric oxide synthase expression by macrophage purinoreceptors and calcium. J Biol Chem271, 337–342.
158.
HiroseM, IshiharaK, SaitoA, NakagawaT, YamadaS, OkudaK (2001) Expression of cytokines and inducible nitric oxide synthase in inflamed gingival tissue. J Periodontol72, 590–597.
159.
WangX, DesaiK, ClausenJT, WuL (2004) Increased methylglyoxal and advanced glycation end products in kidney from spontaneously hypertensive rats. Kidney Int66, 2315–2321.
160.
OgawaS, NakayamaK, NakayamaM, MoriT, MatsushimaM, OkamuraM, SendaM, NakoK, MiyataT, ItoS (2010) Methylglyoxal is a predictor in type 2 diabetic patients of intima-media thickening and elevation of blood pressure. Hypertension56, 471–476.
161.
KilhovdBK, BergTJ, BirkelandKI, ThorsbyP, HanssenKF (1999) Serum levels of advanced glycation end products are increased in patients with type 2 diabetes and coronary heart disease. Diabetes Care22, 1543–1548.
162.
BrosseronF, KrauthausenM, KummerM, HenekaMT (2014) Body fluid cytokine levels in mild cognitive impairment and Alzheimer’s disease: A comparative overview. Mol Neurobiol50, 534–544.
163.
FeinkohlI, PriceJF, StrachanMW, FrierBM (2015) The impact of diabetes on cognitive decline: Potential vascular, metabolic, and psychosocial risk factors. Alzheimers Res Ther7, 46.
164.
MarioniRE, StrachanMW, ReynoldsRM, LoweGD, MitchellRJ, FowkesFG, FrierBM, LeeAJ, ButcherI, RumleyA, MurrayGD, DearyIJ, PriceJF (2010) Association between raised inflammatory markers and cognitive decline in elderly people with type 2 diabetes: The Edinburgh Type 2 Diabetes Study. Diabetes Care59, 710–713.
165.
WhitmerRA, KarterAJ, YaffeK, QuesenberryCPJr, SelbyJV (2009) Hypoglycemic episodes and risk of dementia in older patients with type 2 diabetes mellitus. JAMA301, 1565–1572.
166.
WhitmerRA (2007) Type 2 diabetes and risk of cognitive impairment and dementia. Curr Neurol Neurosci Rep7, 373–380.
167.
MünchG, CunninghamAM, RiedererP, BraakE (1998) Advanced glycation endproducts are associated with Hirano bodies in Alzheimer’s disease. Brain Res796, 307–310.
168.
KuhlaB, LüthHJ, HaferburgD, BoeckK, ArendtT, MünchG (2005) Methylglyoxal, glyoxal, and their detoxification in Alzheimer’s disease. Ann N Y Acad Sci1043, 211–216.
169.
WebsterJ, UrbanC, BerbaumK, LoskeC, AlparA, GärtnerU, de ArribaSG, ArendtT, MünchG (2005) The carbonyl scavengers aminoguanidine and tenilsetam protect against the neurotoxic effects of methylglyoxal. Neurotox Res7, 95–101.
170.
Dukic-StefanovicS, SchinzelR, RiedererP, MünchG (2001) AGES in brain ageing: AGE-inhibitors as neuroprotective and anti-dementia drugs?Biogerontology2, 19–34.
171.
MünchG, TaneliY, SchravenE, SchindlerU, SchinzelR, PalmD, RiedererP (1994) The cognition-enhancing drug tenilsetam is an inhibitor of protein crosslinking by advanced glycosylation. J Neural Transm Park Dis Dement Sect8, 193–208.
